Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

2.45USD
18 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.45
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
307,729
52-wk High
$4.09
52-wk Low
$1.59

Select another date:

Thu, Apr 5 2018

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update

* BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION

BRIEF-Antares Pharma Q4 Loss Per Share $0.02

* ANTARES PHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

BRIEF-Antares Pharma Provides Xyosted Regulatory Update

* ANTARES PHARMA INC - TYPE A MEETING HAS BEEN SCHEDULED WITH U.S. FOOD AND DRUG ADMINISTRATION ON FEBRUARY 21, 2018 FOR XYOSTED

BRIEF-Antares Pharma Requests Type A Meeting With FDA Regarding Xyosted

* ANTARES PHARMA - WRITTEN REQUEST FOR A TYPE A MEETING HAS BEEN SUBMITTED TO FDA IN RESPONSE TO CRL RECEIVED REGARDING NDA FOR XYOSTED Source text for Eikon: Further company coverage:

BRIEF-Antares Pharma Q3 loss per share $0.03

* Antares Pharma reports third quarter 2017 operating and financial results

BRIEF-Antares Pharma receives complete response letter from FDA for Xyosted

* Antares pharma receives complete response letter from the fda for Xyosted

Select another date: